Natalizumab Therapy Modulates miR-155, miR-26a and Proinflammatory Cytokine Expression in MS Patients.

Natalizumab Therapy Modulates miR-155, miR-26a and Proinflammatory Cytokine Expression in MS Patients.

MicroRNAs fine-tune the regulation of Th1/Th17 lymphocyte subsets in multiple sclerosis. We investigated the expression of miRNAs (previously associated with mycobacterial and viral infections) in MS patients and healthy donors (HD) following 6 months natalizumab therapy. In addition, Th1/Th17 cytok...

Full description

Bibliographic Details
Main Authors: Giuseppe Mameli, Giannina Arru, Elisa Caggiu, Magdalena Niegowska, Stefania Leoni, Giordano Madeddu, Sergio Babudieri, Gian Pietro Sechi, Leonardo A Sechi
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4911163?pdf=render

Internet

http://europepmc.org/articles/PMC4911163?pdf=render

Similar Items